Last updated on April 24, 2014 at 17:35 EDT

Global Healthcare Leader Deploys QUOSA’s Literature Management Tools

October 22, 2013

PHILADELPHIA, October 22, 2013 /PRNewswire/ –

Sanofi will use QUOSA, part of Elsevier Life Science Solutions for drug

discovery and development, to support adverse event monitoring

Elsevier [http://www.elsevier.com ], a world-leading provider of scientific, technical
and medical information products and services, today announced that Sanofi, one of the
world’s leading pharmaceutical organizations, has implemented QUOSA’s
[http://www.elsevier.com/online-tools/quosa?utm_source=Corporate_Markets&utm_medium=pr&utm_content=release1&utm_campaign=pbt_qs_pr_releases_q22013 ]
literature management tools to
automate adverse event monitoring. QUOSA powers the retrieval, storage, tagging and
annotation of relevant case reports, allowing for the creation of a centralized repository
of product-related scientific literature. This centralized repository supports Sanofi’s
Pharmacovigilance team in drug safety and adverse event monitoring, ensuring patient
safety and compliance with regulatory reporting requirements in all the markets in which
it operates.

“Pharmaceutical companies are continually challenged to ensure regulatory compliance
is met. This is no easy task with limited resources, an ever-growing number of literature
articles and an increasing portfolio of drugs to be tracked. Left untamed, this presents
significant risks in compliance and crucially, in patient safety,” said Michael Rai,
General Manager of QUOSA at Elsevier. “In response to our many conversations with
Information Professionals, we have finely tuned QUOSA to complement current processes to
provide a stable, efficient and scalable solution which continues to evolve with future
needs. We look forward to working with Sanofi to manage this flow of information and
support its Pharmacovigilance teams’ work.”

QUOSA provides software and services to life science companies, enabling them to
centralize repositories of scientific literature related to drugs and medical devices, as
well as receive alerts about new articles related to their products and other market
developments. These not only help Pharmacovigilance and Medical Affairs teams carry out
their work effectively and quickly, they also ensure sound information management
processes and compliance with regulatory requirements.

QUOSA’s pharmacovigilance solution features three elements that help companies meet
their literature tracking objectives. First, Elsevier provides prompt customized
professional services through its dedicated Life Sciences Integration Services team.
Second, QUOSA can be used as either a desktop application or browser-based technology,
facilitating secure and scalable information sharing across multiple regions. Third, QUOSA
easily integrates with already existing literature resources like third-party publisher
platforms, A&I databases like Embase, and document delivery vendors.

QUOSA is part of Elsevier Life Science Solutions, a suite of interoperable,
domain-specific, decision support tools which span the discovery and development workflow;
including TargetInsights(R), Pathway Studio(TM), Reaxys (R), Reaxys (R) Medicinal
Chemistry, PharmaPendium(R) and Embase(R).

About Elsevier

Elsevier is a world-leading provider of scientific, technical and medical information
products and services. The company works in partnership with the global science and health
communities to publish more than 2,000 journals, including The Lancet
[http://www.thelancet.com ] and Cell [http://www.cell.com ], and close to 20,000 book
titles, including major reference works from Mosby and Saunders. Elsevier’s online
solutions include ScienceDirect [http://www.sciencedirect.com ], Scopus
[http://www.scopus.com ], SciVal [http://info.scival.com ], Reaxys
[http://www.elsevier.com/reaxys ], ClinicalKey [https://www.clinicalkey.com ] and Mosby’s
Suite [http://www.confidenceconnected.com ], which enhance the productivity of science and
health professionals, helping research and health care institutions deliver better
outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier [http://www.elsevier.com ]
employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC
[http://www.reedelsevier.com/Pages/Home.aspx ], a world leading provider of professional
information solutions. The group employs more than 30,000 people, including more than
15,000 in North America. Reed Elsevier Group PLC is owned equally by two parent companies,
Reed Elsevier PLC and Reed Elsevier NV. Their shares are traded on the London, Amsterdam
and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam:
REN; New York: RUK and ENL.

        Media contact
        Liz Griffioen

SOURCE Elsevier

Source: PR Newswire